Repligen Co. (NASDAQ:RGEN) Shares Bought by Keeler Thomas Management LLC

Keeler Thomas Management LLC grew its position in Repligen Co. (NASDAQ:RGEN) by 68.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,979 shares of the biotechnology company’s stock after acquiring an additional 3,662 shares during the period. Keeler Thomas Management LLC’s holdings in Repligen were worth $1,294,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of RGEN. Blue Trust Inc. increased its stake in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares in the last quarter. Resources Management Corp CT ADV acquired a new stake in Repligen in the third quarter valued at approximately $37,000. Quarry LP increased its position in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares during the period. Finally, Global Retirement Partners LLC lifted its position in shares of Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 129 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

NASDAQ:RGEN opened at $164.74 on Tuesday. Repligen Co. has a one year low of $113.50 and a one year high of $203.13. The stock has a market cap of $9.23 billion, a PE ratio of -323.02, a P/E/G ratio of 4.54 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a 50 day moving average price of $155.30 and a 200 day moving average price of $148.57.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Equities research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Canaccord Genuity Group boosted their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday. Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Royal Bank of Canada raised their price target on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research note on Friday. Finally, TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $181.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.